

NCT ID	NCT00001823
Title	Evaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols
Phase	
Date Added	1999-11-04
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05482516
Title	Evaluating Novel Therapies in ctDNA Positive GI Cancers
Phase	Phase 3
Date Added	2022-08-01
Location	District of Columbia, United States New Jersey, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Atezolizumab, Bevacizumab, Avastin, Tecentriq
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06060704
Title	Envafoimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
Phase	Phase 2
Date Added	2023-09-29
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Bevacizumab, Envafoimab, Trifluridine/Tipiracil, Avastin, Lonsurf
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT02453620
Title	Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
Phase	Phase 1
Date Added	2015-05-25
Location	California, United States Connecticut, United States Maryland, United States Pennsylvania, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy
Tags	MSS/ MMRp
NCT ID	NCT04017650
Title	Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Phase	Phase 1, Phase 2
Date Added	2019-07-12
Location	Texas, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	cetuximab, encorafenib, Nivolumab
Tags	MSS/ MMRp
NCT ID	NCT06923761
Title	EMITT-1 (ERAP Mediated Immunozeptidome Targeting Trial – 1)
Phase	Phase 1
Date Added	2025-04-11
Location	Australia France Spain United Kingdom
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd
NCT ID	NCT04853017
Title	ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)
Phase	Phase 1
Date Added	2021-04-21
Location	California, United States Colorado, United States Iowa, United States Massachusetts, United States Missouri, United States New York, United States Tennessee, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04730544
Title	Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer (NIPISAFE)
Phase	Phase 2
Date Added	2021-01-29
Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab
Tags	MSI-H/ MMRd

NCT ID	NCT06008119
Title	Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Phase	Phase 3
Date Added	2023-08-23
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab, Tunlametinib plus Vemurafenib
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT05799443
Title	Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Phase	Phase 2
Date Added	2023-04-05
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	cetuximab, Irinotecan Hydrochloride, Tislelizumab
Tags	MSI-H/ MMRd, MSS/ MMRp